AstraZeneca announced that BRILINTA showed promising results in reducing the risk of heart attacks in patients.
Brilinta is an anti clotting drug that doctors usually prescribe after a year of heart attack. Plavix, which is the generic name of the drug, significantly lessen the heart issues of the patients. The drug is relatively more effective as compared to aspirin.
The main objective of the trial, which is known as PEGASUS, was to determine the affect of Brilinta on patients with acute coronary syndrome. The company intended to ascend the number of buyers with this trial.
The recent clinical trial will surely increase the sales of Brilinta. Currently, the drug generates revenue of around $3.5 billion every year. However, the head of the British pharmaceutical company has set a goal to produce income of nearly $45 billion till 2023.
The pharmaceutical company released the outcome of clinical trial on Wednesday. Shortly after the result of the trial, the shares of the company climbed 1.5 percent in the market of London.
Eric Le Berrigaud, n analyst at Bryan Garnier & Co. in Paris states that it seems like investors are merely waiting for the extensive report of the study. The report will evidently demonstrate the margin of improvements
In comparison, there are numerous other blood thinner drugs are available in the markets. For instance, Sanofi’s Plavix comes with a cheap price tag as compared to Brilinta
